• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Top 5 Articles About Healthcare and Drug Costs in 2023

News
Article

Articles about Humira biosimilars, over-the-counter hearing aids and specialty drugs were among those about healthcare and drug costs that had the most pageviews on the MHE website in 2023.

Here are the top five most-viewed articles about healthcare and drug costs that were posted on the Managed Healthcare Executive website in 2023.

The Future of Savings in Humira Biosimilars Drug Costs Are Low

As a Humira biosimilars are set to enter the market this year, it seems to be unlikely that they will drive down drug costs in the future.

Read more

No Prescription Needed. But Will Insurers Cover OTC Hearing Aids?


Commercial plans haven’t traditionally covered hearing aids.

Read more

Tis Full and Very, Very Expensive: the 2023 Specialty Drug Pipeline | AMCP 2023

Specialty drugs are expected to comprise 80% of the FDA approvals this year. Among them are gene therapies for hemophilia A and Duchenne muscular dystrophy priced at between $2 million and $3 million.

Read more

Inpefa, a New Heart Failure Drug, Surpasses Cost-Effectiveness Threshold

Inpefa (sotagliflozin) added 0.39 quality of life years at an incremental lifetime cost of $29,449 for an incremental cost-effectiveness ratio of $75,510 per quality-of-life year gained, according to the study that was sponsored by the drug's maker, Lexicon Pharmaceuticals.

Read more

Off-label Use of Avastin in Diabetic Macular Edema More Cost-Effective Than Eylea

Starting with Avastin to treat patients with diabetic macular edema — and switching to Eylea if patients don’t have a response — could result in savings of more than $125 million.

Read more

Related Videos
Video 6 - "Navigating Insurance Coverage for Prescription Digital Therapeutics"
Video 5 - "FDA Approval Pathway for Prescription Digital Therapeutics"
Video 8 - "Gaps in Evidence Generation for Digital Therapeutics"
Video 7 - "Adoption Lessons For Payers"
Video 10 - "Managing Self Care"
Video 3 - "Embracing and Improving Access to Technology Tools"
Video 4 - "Assessing the Cost-Effectiveness of Prescription Digital Therapeutics "
Related Content
© 2024 MJH Life Sciences

All rights reserved.